61 results for "Burger, Michael"
Showing 21–40 · 0.16 seconds · RSS
-
Journal Article Full text
Ventriculoperitoneal Shunts Equipped with On-Off Valves for Intraventricular Therapies in Patients with Communicating Hydrocephalus due to Leptomeningeal Metastases
Ventriculoperitoneal shunts equipped with a reservoir and a valve to manually switch off the shunt function can be used for intraventricular injections of therapeutics in patients suffering from a communicating hydrocephalus caused by leptomeningeal metastases. These shunt devices avoid the risk of…
-
Journal Article Full text
IMMU-15. Local CAR-NK cell therapy in combination with systemic checkpoint inhibition induces anti-tumor responses even in distant tumor locations in an immunocompetent glioblastoma mouse model
BACKGROUND: The glioblastoma (GB) tumor microenvironment (TME) is characterized by pronounced immunosuppression, with PD-L1 expression both on glioma cells and microglia, and exhaustion of infiltrating immune cells. We showed previously that a combination of local injection of HER2-specific…
-
Journal Article Full text
Bevacizumab for Patients with Recurrent Multifocal Glioblastomas
In patients with glioblastoma, antiangiogenic therapy with bevacizumab (BEV) has been shown to improve progression-free survival (PFS), but not overall survival (OS). Especially in patients with an unusual infiltrative phenotype as seen in multifocal glioblastoma, the use of BEV therapy is still…
-
Journal Article Full text
ErbB2/Her2-specific NK cells for adoptive immunotherapy of glioblastoma
-
Journal Article Full text
Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival
Epidermal growth factor receptor (EGFR) and its mutant form EGFRvIII are overexpressed in a large proportion of glioblastomas (GBM). Immunotherapy with an EGFRvIII-specific vaccine has shown efficacy against GBM in clinical studies. However, immune escape by antigen-loss variants and lack of…
-
Journal Article Full text
State Public Nuisance Claims and Climate Change Adaptation
This Article explores the potential for state public nuisance claims to facilitate adaptation, resource protection, and other climate change responses by coastal communities in California. The California public nuisance actions represent just the latest chapter in efforts to spur responses to…
-
Journal Article Full text
CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy
Glioblastoma (GB) is the most common and aggressive primary brain tumor in adults and currently incurable. Despite multimodal treatment regimens, median survival in unselected patient cohorts is
-
Journal Article Full text
Local Anesthetic-Induced Central Nervous System Toxicity during Interscalene Brachial Plexus Block: A Case Series Study of Three Patients
Local anesthetics are commonly administered by nuchal infiltration to provide a temporary interscalene brachial plexus block (ISB) in a surgical setting. Although less commonly reported, local anesthetics can induce central nervous system toxicity. In this case study, we present three patients with…
-
Journal Article Full text
The Disaster Management Complex: Law’s Adaptations in Times of Climate Disaster
The Anthropocene is marked by constant climate-related disasters and defined by the urgent need to foster and implement adaptations to future climate impacts that reduce disaster risk. The intensity, frequency, and severity of extreme weather events continue to rise even as nations and corporations…
-
Journal Article Full text
Calcitriol Promotes Differentiation of Glioma Stem-Like Cells and Increases Their Susceptibility to Temozolomide
SIMPLE SUMMARY: Cancer cells with a stem-like phenotype that are thought to be highly tumorigenic are commonly described in glioblastoma, the most common primary adult brain cancer. This phenotype comprises high self-renewal capacity and resistance against chemotherapy and radiation therapy…
-
Journal Article Full text
CTIM-30. A PHASE 1B, OPEN-LABEL, DOSE-ESCALATION TRIAL OF THE DELTA-LIKE LIGAND 3 (DLL3)/CD3 IGG-LIKE T CELL ENGAGER, BI 764532, IN PATIENTS WITH DLL3-POSITIVE GLIOMA
BACKGROUND: Patients with progressive diffuse gliomas have limited treatment options. DLL3, a Notch ligand, is expressed on most diffuse gliomas. BI 764532, a humanized IgG-like T cell engager, binds selectively to DLL3-positive cells and promotes T cell-mediated cytotoxicity. Preclinical data…
-
Journal Article Full text
Comparative cross-methodological analysis of the IDH-wildtype glioblastoma tumor microenvironment
PURPOSE: Glioblastoma, IDH-wildtype is a highly aggressive and often recurrent brain malignancy characterized by a profoundly immunosuppressive and heterogeneous tumor microenvironment. In this study, we aimed to systematically compare commonly used immune profiling methodologies. METHODS: We…
-
Journal Article Full text
Disruption of peroxisome proliferator–activated receptor γ coactivator (PGC)-1α reverts key features of the neoplastic phenotype of glioma cells
The peroxisome proliferator–activated receptor γ coactivator (PGC)-1α is a master regulator of mitochondrial biogenesis and controls metabolism by coordinating transcriptional events. Here, we interrogated whether PGC-1α is involved in tumor growth and the metabolic flexibility of glioblastoma…
-
Journal Article Full text
Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine
In previous trials, bevacizumab failed to prolong the overall survival time in newly diagnosed glioblastoma and at the first recurrence. Randomized clinical trials at the second or further recurrence following the failure of radiotherapy, temozolomide and lomustine, and retrospective analyses…
-
Journal Article Full text
Non-Invasive Measurement of Drug and 2-HG Signals Using (19)F and (1)H MR Spectroscopy in Brain Tumors Treated with the Mutant IDH1 Inhibitor BAY1436032
SIMPLE SUMMARY: Targeted therapies are of growing interest to physicians in cancer treatment. These drugs target specific genes and proteins involved in the growth and survival of cancer cells. Brain tumor therapy is complicated by the fact that not all drugs can penetrate the blood brain barrier…
-
Journal Article Full text
Immunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins in Human Brain Tumors
BACKGROUND: Current pathological diagnostics include the analysis of (epi-)genetic alterations as well as oncogenic pathways. Deregulated mammalian target of rapamycin complex 1 (mTORC1) signaling has been implicated in a variety of cancers including malignant gliomas and is considered a promising…
-
Journal Article Full text
RARE-35. DABRAFENIB IN PATIENTS WITH RECURRENT, BRAF V600E MUTATED MALIGNANT GLIOMA AND LEPTOMENINGEAL DISEASE
BRAF V600E mutations occur frequently in malignant melanoma but are rare in most glioma subtypes. Besides more benign brain tumors, like ganglioglioma, dysembryoblastic neuroepithelial tumours and supratentorial pilocytic astrocytomas, only pleomorphic xanthoastrocytomas (50-78%) and epitheloid…
-
Journal Article Full text
TMIC-39. SPATIAL MULTIOMICS PROFILING REVEALS HETEROGENEITY OF B:T CELL INTERACTIONS AND PLASMA CELL FORMATION IN TERTIARY LYMPHOID STRUCTURES IN HUMAN GLIOMAS
Adult-type diffuse gliomas, the most common primary brain tumours, remain a clinical challenge in oncology with limited treatment options, restricted anti-tumour immune response and a dismal patient prognosis. Despite their immunosuppressive microenvironment, the formation of lymphoid aggregates…
-
Journal Article Full text
Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease
BRAF V600E mutations occur frequently in malignant melanoma, but are rare in most malignant glioma subtypes. Besides, more benign brain tumors such as ganglioglioma, dysembryoblastic neuroepithelial tumours and supratentorial pilocytic astrocytomas, only pleomorphic xanthoastrocytomas (50–78%) and…